Serina Therapeutics develops drug candidates using its POZ polymer delivery technology, with a lead treatment for Parkinson's disease. SER reports earnings on Wed, Nov 18, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 10 | BTIG | Reiterated | Buy | |
| Jul 1 | BTIG | Initiated | Buy |
Seasonality
How SER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in SER in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SER is in one of them and how their past SER trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SER in an article yet. Here's the latest on the wider market.
About Serina Therapeutics
Serina Therapeutics is a biotechnology company based in Huntsville, Alabama. It develops drug candidates that use its proprietary POZ polymer technology, which is designed to control how a drug is released and how long it stays active in the body. Its lead candidate, SER 252, is being developed to treat Parkinson's disease and is in clinical development. The company also plans to work with pharmaceutical partners on other uses of its platform, including RNA-based therapies and antibody drug conjugates.
- Headquarters
- Huntsville, AL